Ginkgo Bioworks Holdings Management
Management criteria checks 3/4
Ginkgo Bioworks Holdings' CEO is Jason Kelly, appointed in Jan 2008, has a tenure of 16.92 years. total yearly compensation is $262.50K, comprised of 95.2% salary and 4.8% bonuses, including company stock and options. directly owns 4.03% of the company’s shares, worth $18.69M. The average tenure of the management team and the board of directors is 6.4 years and 1.6 years respectively.
Key information
Jason Kelly
Chief executive officer
US$262.5k
Total compensation
| CEO salary percentage | 95.2% |
| CEO tenure | 16.9yrs |
| CEO ownership | 4.0% |
| Management average tenure | 6.4yrs |
| Board average tenure | 1.6yrs |
Recent management updates
Recent updates
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Just Released Its Third-Quarter Earnings: Here's What Analysts Think
Nov 15
Ginkgo Bioworks: Not Enough Progress
Nov 13Revenues Tell The Story For Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) As Its Stock Soars 33%
Oct 04Ginkgo Bioworks: Here Comes The Test
Aug 22The Price Is Right For Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Even After Diving 27%
Aug 16Ginkgo Bioworks: Losing A Major Supporter
Jun 25Ginkgo Bioworks Holdings, Inc.'s (NYSE:DNA) Share Price Is Still Matching Investor Opinion Despite 47% Slump
Jun 18Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
May 11Ginkgo Bioworks: Broken Narrative
May 10Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Stocks Pounded By 27% But Not Lagging Industry On Growth Or Pricing
Apr 26Newsflash: Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Analysts Have Been Trimming Their Revenue Forecasts
Mar 06With Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) It Looks Like You'll Get What You Pay For
Mar 01Ginkgo Bioworks: More Awful Revenue Guidance
Mar 01Ginkgo Bioworks At The Intersection Of Cutting-Edge Technology And Financial Disappointment
Jan 26Ginkgo Bioworks: Strategic Shifts Amidst Financial Uncertainty
Dec 20Ginkgo Bioworks: A Long Way To Go
Nov 21News Flash: 9 Analysts Think Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Earnings Are Under Threat
Nov 13Ginkgo Bioworks: More Revenue Issues
Nov 13Ginkgo Bioworks Holdings, Inc.'s (NYSE:DNA) Share Price Is Still Matching Investor Opinion Despite 30% Slump
Nov 10Porter's 5 Forces Suggest That Ginkgo Is A Buy
Oct 25Ginkgo Bioworks: Products Progressing Towards Market
Oct 10Ginkgo Bioworks: Google Partnership Increases Runway (Rating Upgrade)
Aug 30Ginkgo Bioworks: Lack Of Progress Is A Concern
Aug 18Ginkgo Bioworks: Major Revenue Trouble (Ratings Downgrade)
Aug 10Ginkgo Bioworks: Tremendous Potential, But Strong Short Term Headwinds
Jun 23Ginkgo Bioworks: Avoid For Now
Feb 20Ginkgo: Standardizing Offerings For Growth
Feb 08Ginkgo Bioworks: Increasing Focus On Pharma And Biotech
Jan 12CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$651m |
| Jun 30 2024 | n/a | n/a | -US$898m |
| Mar 31 2024 | n/a | n/a | -US$854m |
| Dec 31 2023 | US$263k | US$250k | -US$893m |
| Sep 30 2023 | n/a | n/a | -US$857m |
| Jun 30 2023 | n/a | n/a | -US$1b |
| Mar 31 2023 | n/a | n/a | -US$2b |
| Dec 31 2022 | US$263k | US$250k | -US$2b |
| Sep 30 2022 | n/a | n/a | -US$4b |
| Jun 30 2022 | n/a | n/a | -US$3b |
| Mar 31 2022 | n/a | n/a | -US$2b |
| Dec 31 2021 | US$381m | US$250k | -US$2b |
| Sep 30 2021 | n/a | n/a | -US$276m |
| Jun 30 2021 | n/a | n/a | -US$200m |
| Mar 31 2021 | n/a | n/a | -US$175m |
| Dec 31 2020 | US$11m | US$250k | -US$127m |
Compensation vs Market: Jason's total compensation ($USD262.50K) is below average for companies of similar size in the US market ($USD2.25M).
Compensation vs Earnings: Jason's compensation has been consistent with company performance over the past year.
CEO
Jason Kelly (43 yo)
16.9yrs
Tenure
US$262,500
Compensation
Dr. Jason Kelly serves as Director of Genomatica, Inc. Dr. Kelly founded Ginkgo Bioworks, Inc. (nka:Ginkgo Bioworks Holdings, Inc.) in 2008 and serves as its Chief Executive Officer and has been Director s...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 16.9yrs | US$262.50k | 4.03% $ 18.7m | |
| Founder | 16.9yrs | US$262.50k | 4.39% $ 20.3m | |
| Chief Financial Officer | 4.1yrs | US$1.69m | 0.090% $ 417.8k | |
| Founder | no data | no data | no data | |
| Founder | no data | no data | 4.5% $ 20.9m | |
| Founder | no data | no data | 4.38% $ 20.3m | |
| Chief Accounting Officer | 1.6yrs | no data | 0.013% $ 60.0k | |
| General Counsel & Secretary | no data | no data | no data | |
| Senior Vice President of Corporate Development | no data | no data | no data | |
| Head of People | 6.9yrs | no data | no data | |
| Head of Design | 6.2yrs | no data | no data | |
| Head of Omics & Analytical Chemistry | 6.4yrs | no data | no data |
6.4yrs
Average Tenure
43yo
Average Age
Experienced Management: DNA's management team is seasoned and experienced (6.4 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 16.9yrs | US$262.50k | 4.03% $ 18.7m | |
| Founder | 16.9yrs | US$262.50k | 4.39% $ 20.3m | |
| Member of Biopharma Advisory Board | less than a year | no data | no data | |
| Member of Biopharma Advisory Board | less than a year | no data | no data | |
| Independent Director | 3.3yrs | US$459.38k | 0.49% $ 2.3m | |
| Member of Biopharma Advisory Board | less than a year | no data | no data | |
| Independent Director | 8.9yrs | US$477.50k | 0.063% $ 292.7k | |
| Independent Director | 2.3yrs | US$448.67k | 0.0079% $ 36.6k | |
| Member of Biopharma Advisory Board | less than a year | no data | no data | |
| Independent Chairman of the Board | 9.9yrs | US$485.19k | 0.12% $ 538.0k | |
| Member of Biopharma Advisory Board | less than a year | no data | no data | |
| Member of Biopharma Advisory Board | less than a year | no data | no data |
1.6yrs
Average Tenure
59.5yo
Average Age
Experienced Board: DNA's board of directors are not considered experienced ( 1.6 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/20 00:32 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Ginkgo Bioworks Holdings, Inc. is covered by 10 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Derik de Bruin | BofA Global Research |
| Michael Ryskin | BofA Global Research |
| Mark Massaro | BTIG |